Osaic Holdings’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-32,873
| Closed | -$705K | – | 8041 |
|
|
2026
Q1 | $705K | Sell |
32,873
-6,617
| -17% | -$93.2K | ﹤0.01% | 3175 |
|
|
2025
Q4 | $368K | Buy |
39,490
+2,195
| +6% | +$18.3K | ﹤0.01% | 3612 |
|
|
2025
Q3 | $261K | Hold |
37,295
| – | – | ﹤0.01% | 3996 |
|
|
2025
Q2 | $214K | Sell |
32,881
-32,430
| -50% | -$223K | ﹤0.01% | 3883 |
|
|
2025
Q1 | $518K | Buy |
65,311
+32,459
| +99% | +$350K | ﹤0.01% | 2840 |
|
|
2024
Q4 | $416K | Buy |
32,852
+32,421
| +7,522% | +$451K | ﹤0.01% | 2959 |
|
|
2024
Q3 | $6K | Buy |
431
+263
| +157% | +$3.75K | ﹤0.01% | 6113 |
|
|
2024
Q2 | $2.32K | Buy |
+168
| New | +$2.46K | ﹤0.01% | 6542 |
|
|
2023
Q4 | – | Sell |
-24
| Closed | -$294 | – | 7339 |
|
|
2023
Q3 | $294 | Buy |
24
+10
| +71% | +$130 | ﹤0.01% | 7089 |
|
|
2023
Q2 | $167 | Sell |
14
-169
| -92% | -$2.21K | ﹤0.01% | 7234 |
|
|
2023
Q1 | $2.44K | Buy |
+183
| New | +$3.58K | ﹤0.01% | 6632 |
|
|
2022
Q3 | – | Sell |
-1
| Closed | – | – | 7297 |
|
|
2022
Q2 | $0 | Buy |
+1
| New | – | ﹤0.01% | 7392 |
|
Other funds holding DAWN
Osaic Holdings's DAWN Position: Q2 2026 in Review
Osaic Holdings sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 32,873 shares — an estimated $705K sold.
Osaic Holdings first reported a position in DAWN in Q2 2022 and held it in 12 quarters. The position peaked at $705K in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Osaic Holdings reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Osaic Holdings sold 32,873 Day One Biopharmaceuticals shares in Q2 2026, an estimated $705K.
- Osaic Holdings first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 12 quarters.
- Osaic Holdings's Day One Biopharmaceuticals position peaked at $705K in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.